Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Report
November 14, 2014
Hepatitis C Virus (How Will All-Oral, Interferon-Free Antiviral Regimens Influence Physician and Payer Attitudes Toward Treatment and Reimbursement in the Cost-Constrained EU5?) | Physician & Payer Forum | EU5 | 2014
In January 2014, the European Medicines Agency granted marketing authorization to the first nucleotide polymerase inhibitor, sofosbuvir (Gilead’s Sovaldi), for the treatment of hepatitis C virus…
Report
October 23, 2014
Hepatitis C Virus: How Will More Efficacious Direct-Acting Antivirals Influence US Prescribing and Reimbursement for This Dynamic Indication? | Physician & Payer Forum | US | 2014
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
Report
June 9, 2014
Hepatitis C Virus (Primary Care Physicians in an Interferon-Free World: How Will the Availability of Safer and More Effective Oral Therapies Impact the Role of PCPs in Treating HCV Patients?) | Physician & Payer Forum | US | 2014
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
